{"doc_id": "si-2023-0011-reg-1", "parent_doc_id": "si-2023-0011", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 11 of 2023", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2023, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) Regulations 2023. \n\n(2) The Principal Regulations, the Medicinal Products (Prescription and \nControl of Supply) (Amendment) Regulations 2005 (S.I. No. 510 of 2005), the \nMedicinal Products (Prescription and Control of Supply) (Amendment) \nRegulations 2007 (S.I. No. 201 of 2007), Part 4 of the Medicinal Products \n(Control of Placing on the Market) Regulations 2007 (S.I. No. 540 of 2007), \nthe Medicinal Products (Prescription and Control of Supply) (Amendment) \nRegulations 2008 (S.I. No. 512 of 2008), the Medicinal Products (Prescription \nand Control of Supply) (Amendment) Regulations 2009 (S.I. No. 442 of 2009), \nthe Medicinal Products (Prescription and Control of Supply) (Amendment) \nRegulations 2011 (S.I. No. 525 of 2011), the Medicinal Products (Prescription \nand Control of Supply) (Amendment) Regulations 2014 (S.I. No. 300 of 2014), \nthe Medicinal Products (Prescription and Control of Supply) (Amendment) \n(No. 2) Regulations 2014 (S.I. No. 504 of 2014), the Medicinal Products \n(Prescription and Control of Supply) (Amendment) Regulations 2015 (S.I. No. \n87 of 2015), the Medicinal Products (Prescription and Control of Supply) \n(Amendment) (No. 2) Regulations 2015 (S.I. No. 449 of 2015), the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) Regulations 2018 \n(S.I. No. 530 of 2018), Medicinal Products (Prescription and Control of \nSupply) (Amendment) Regulations 2020 (S.I. No. 98 of 2020), the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) (No. 2) \nRegulations 2020 (S.I. No. 177 of 2020), the Medicinal Products (Prescription \nand Control of Supply) (Amendment) (No. 3) Regulations 2020 (S.I. No. 204 \nof 2020), the Medicinal Products (Prescription and Control of Supply) \n(Amendment) (No. 4) Regulations 2020 (S.I. No. 241 of 2020), the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) (No. 5) \nRegulations 2020 S.I. No. 401 of 2020), the Medicinal Products (Prescription \nand Control of Supply) (Amendment) (No. 6) Regulations 2020 (S.I. No. 614 \nof 2020), the Medicinal Products (Prescription and Control of Supply) \n(Amendment) (No. 7) Regulations 2020 (S.I. No. 698 of 2020), the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) Regulations 2021 \n(S.I. No. 2 of 2021), the Medicinal Products (Prescription and Control of \nSupply) (Amendment) (No. 2) Regulations 2021 (S.I. No. 8 of 2021), the \nMedicinal Products (Prescription and Control of Supply) (Amendment) (No. 3) \nRegulations 2021 (S.I. No. 43 of 2021), the Medicinal Products (Prescription \nand Control of Supply) (Amendment) (No. 4) Regulations 2021 (S.I. No. 81 of \nthe Medicinal Products (Prescription and Control of Supply) \n2021), \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 27th January, 2023. \n\n \n \n \n \n \n\f[11] 3 \n\n(Amendment) (No. 5) Regulations 2021 (S.I. No. 130 of 2021), the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) (No. 6) \nRegulations 2021 (S.I. No. 155 of 2021), the Medicinal Products (Prescription \nand Control of Supply) (Amendment) (No. 7) Regulations 2021 (S.I. No. 245 \nof 2021), the Medicinal Products (Prescription and Control of Supply) \n(Amendment) (No. 8) Regulations 2021 (S.I. No. 411 of 2021), the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) (No. 9) \nRegulations 2021 (S.I. No. 492 of 2021), the Medicinal Products (Prescription \nand Control of Supply) (Amendment) (No. 10) Regulations 2021 (S.I. No. 511 \nof 2021), the Medicinal Products (Prescription and Control of Supply) \n(Amendment) (No. 11) Regulations 2021 (S.I. No. 558 of 2021), the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) (No. 12) \nRegulations 2021 (S.I. No. 578 of 2021), the Medicinal Products (Prescription \nand Control of Supply) (Amendment) (No. 13) Regulations 2021 (S.I. No. 605 \nof 2021), the Medicinal Products (Prescription and Control of Supply) \n(Amendment) (No. 14) Regulations 2021 (S.I. No. 692 of 2021), the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) (No. 15) \nRegulations 2021 (S.I. No. 718 of 2021), the Medicinal Products (Prescription \nand Control of Supply) (Amendment) Regulations 2022 (S.I. No. 32 of 2022), \nthe Medicinal Products (Prescription and Control of Supply) (Amendment) \n(No. 2) Regulations 2022 (S.I. No. 57 of 2022), the Medicinal Products \n(Prescription and Control of Supply) (Amendment) (No. 3) Regulations 2022 \n(S.I. No. 84 of 2022), the Medicinal Products (Prescription and Control of \nSupply) (Amendment) (No. 4) Regulations 2022 (S.I. No. 402 of 2022), the \nRegulations of 2022 and these Regulations may be cited together as the \nMedicinal Products (Prescription and Control of Supply) Regulations 2003 to", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) regulation 2023 (2) principal regulation medicinal product (prescription control supply) (amendment) regulation 2005 (s.i no 510 2005) medicinal product (prescription control supply) (amendment) regulation 2007 (s.i no 201 2007) part 4 medicinal product (control placing market) regulation 2007 (s.i no 540 2007) medicinal product (prescription control supply) (amendment) regulation 2008 (s.i no 512 2008) medicinal product (prescription control supply) (amendment) regulation 2009 (s.i no 442 2009) medicinal product (prescription control supply) (amendment) regulation 2011 (s.i no 525 2011) medicinal product (prescription control supply) (amendment) regulation 2014 (s.i no 300 2014) medicinal product (prescription control supply) (amendment) (no 2) regulation 2014 (s.i no 504 2014) medicinal product (prescription control supply) (amendment) regulation 2015 (s.i no 87 2015) medicinal product (prescription control supply) (amendment) (no 2) regulation 2015 (s.i no 449 2015) medicinal product (prescription control supply) (amendment) regulation 2018 (s.i no 530 2018) medicinal product (prescription control supply) (amendment) regulation 2020 (s.i no 98 2020) medicinal product (prescription control supply) (amendment) (no 2) regulation 2020 (s.i no 177 2020) medicinal product (prescription control supply) (amendment) (no 3) regulation 2020 (s.i no 204 2020) medicinal product (prescription control supply) (amendment) (no 4) regulation 2020 (s.i no 241 2020) medicinal product (prescription control supply) (amendment) (no 5) regulation 2020 s.i no 401 2020) medicinal product (prescription control supply) (amendment) (no 6) regulation 2020 (s.i no 614 2020) medicinal product (prescription control supply) (amendment) (no 7) regulation 2020 (s.i no 698 2020) medicinal product (prescription control supply) (amendment) regulation 2021 (s.i no 2 2021) medicinal product (prescription control supply) (amendment) (no 2) regulation 2021 (s.i no 8 2021) medicinal product (prescription control supply) (amendment) (no 3) regulation 2021 (s.i no 43 2021) medicinal product (prescription control supply) (amendment) (no 4) regulation 2021 (s.i no 81 medicinal product (prescription control supply) 2021) notice making statutory instrument published iris oifigiuil 27th january 2023 11 3 (amendment) (no 5) regulation 2021 (s.i no 130 2021) medicinal product (prescription control supply) (amendment) (no 6) regulation 2021 (s.i no 155 2021) medicinal product (prescription control supply) (amendment) (no 7) regulation 2021 (s.i no 245 2021) medicinal product (prescription control supply) (amendment) (no 8) regulation 2021 (s.i no 411 2021) medicinal product (prescription control supply) (amendment) (no 9) regulation 2021 (s.i no 492 2021) medicinal product (prescription control supply) (amendment) (no 10) regulation 2021 (s.i no 511 2021) medicinal product (prescription control supply) (amendment) (no 11) regulation 2021 (s.i no 558 2021) medicinal product (prescription control supply) (amendment) (no 12) regulation 2021 (s.i no 578 2021) medicinal product (prescription control supply) (amendment) (no 13) regulation 2021 (s.i no 605 2021) medicinal product (prescription control supply) (amendment) (no 14) regulation 2021 (s.i no 692 2021) medicinal product (prescription control supply) (amendment) (no 15) regulation 2021 (s.i no 718 2021) medicinal product (prescription control supply) (amendment) regulation 2022 (s.i no 32 2022) medicinal product (prescription control supply) (amendment) (no 2) regulation 2022 (s.i no 57 2022) medicinal product (prescription control supply) (amendment) (no 3) regulation 2022 (s.i no 84 2022) medicinal product (prescription control supply) (amendment) (no 4) regulation 2022 (s.i no 402 2022) regulation 2022 regulation may cited together medicinal product (prescription control supply) regulation 2003", "start_char": 599, "end_char": 5477, "source_path": "downloads\\2023\\2023_0011.pdf", "extraction_method": "pdfminer", "checksum": "sha256:dd9cd72eedc5a9a04462a0c3d90a8a5c34d69e3b70edcdd8cd7ef3d1e55d9f74", "cross_refs": []}
{"doc_id": "si-2023-0011-reg-2023", "parent_doc_id": "si-2023-0011", "section_id": "reg-2023", "section_label": "Regulation 2023.", "si_number": "S.I. No. 11 of 2023", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2023, "heading": null, "text_raw": "2023.", "text_norm": "2023", "start_char": 5477, "end_char": 5485, "source_path": "downloads\\2023\\2023_0011.pdf", "extraction_method": "pdfminer", "checksum": "sha256:dd9cd72eedc5a9a04462a0c3d90a8a5c34d69e3b70edcdd8cd7ef3d1e55d9f74", "cross_refs": []}
{"doc_id": "si-2023-0011-reg-2", "parent_doc_id": "si-2023-0011", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 11 of 2023", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2023, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Principal Regulations” means the Medicinal Products (Prescription and \nControl of Supply) Regulations 2003 (S.I. No. 540 of 2003); \n\n“Regulations of 2022” means the Medicinal Products (Prescription and Control \nof Supply (Amendment) (No. 5) Regulations 2022 (S.I. No. 467 of 2022).", "text_norm": "2 regulations-- principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) regulation 2022 mean medicinal product (prescription control supply (amendment) (no 5) regulation 2022 (s.i no 467 2022)", "start_char": 5485, "end_char": 5799, "source_path": "downloads\\2023\\2023_0011.pdf", "extraction_method": "pdfminer", "checksum": "sha256:dd9cd72eedc5a9a04462a0c3d90a8a5c34d69e3b70edcdd8cd7ef3d1e55d9f74", "cross_refs": []}
{"doc_id": "si-2023-0011-reg-3", "parent_doc_id": "si-2023-0011", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 11 of 2023", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2023, "heading": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations", "text_raw": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations \nof 2022) to the Principal Regulations is amended by inserting the following \nadditional entries: \n\n“ \n\n \n \n \n \n \n\f4 [11] \n\nMedicinal \nproduct \n\nForm and \npresentation \nof the product \nadministered \n\nRoute of \nadministration \n\nColumn 3 \nIntramuscular \n(IM) Injection \n\nIntramuscular \n(IM) Injection \n\nColumn 1 \nComirnaty \n3 \nmicrograms\n/dose \nconcentrate \nfor \ndispersion \nfor \ninjection \nCOVID-19 \nmRNA \nVaccine \n(nucleoside \nmodified) \nPaediatric \npack \n\nComirnaty \nOriginal/O\nmicron \nBA.4-5 (5/5 \nmicrograms\n)/dose \nconcentrate \nfor \ndispersion \nfor injection \nCOVID-19 \nmRNA \nVaccine \n(nucleoside \nmodified) \n\nColumn 2 \nConcentrate \nfor dispersion \nfor injection \n(sterile \nconcentrate) \nin a multidose \nvial that must \nbe diluted \nbefore use. \n\nAfter dilution, \none dose (0.2 \nmL) contains \n3 micrograms \nof \ntozinameran, a \nCOVID-19 \nmRNA \nVaccine \n(embedded in \nlipid \nnanoparticles)\n. \nConcentrate \nfor dispersion \nfor injection \n(sterile \nconcentrate) \nin a multidose \nvial that must \nbe diluted \nbefore use. \n\nAfter dilution \none dose (0.2 \nmL) contains \n5 micrograms \nof \ntozinameran \nand 5 \nmicrograms of \nfamtozinamer\nan, a \nCOVID-19 \nmRNA \nVaccine \n(embedded in \nlipid \nnanoparticles) \n\nIndication \nfor which \nthe \nmedicinal \nproduct may \nbe \nadministere\nd \nColumn 4 \nIndicated for \nactive \nimmunisatio\nn to prevent \nCOVID-19 \ncaused by \nSARS-CoV2 virus, in \nindividuals \naged 6 \nmonths to 4 \nyears at the \ntime of their \nfirst dose. \n\nActive \nimmunisatio\nn to prevent \nCOVID-19 \ncaused by \nSARS-CoV2, in \nchildren \naged 5 to 11 \nyears who \nhave \npreviously \nreceived at \nleast a \nprimary \nvaccination \ncourse \nagainst \nCOVID-19 \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministration \n\nColumn 6 \nAny suitable \nand \nappropriate \nplace, having \nregard to \npublic \nconvenience \nand the need \nto protect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nAny suitable \nand \nappropriate \nplace, having \nregard to \npublic \nconvenience \nand the need \nto protect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nColumn 5 \nIn accordance \nwith relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth, subject to \ninformed consent \nbeing obtained \nfrom a parent or \nguardian. \n\nAdministered as a \ncourse of 3 doses \nof (0.2ml) each. \n\nIn accordance \nwith relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth. \n\nThe product is to \nbe administered to \neligible \nindividuals who \nare 5 -11 years of \nage and have \npreviously \nreceived at least a \nprimary \nvaccination \ncourse against \nCOVID-19. \n\nNotwithstanding \nany directions to \nthe contrary in the \nsummary of \nproduct \ncharacteristics, a \nbooster dose may \nbe administered to \nchildren aged 5 to \n\n \n \n \n \n \n \n \n\f[11] 5 \n\nAny suitable \nand \nappropriate \nplace, having \nregard to \npublic \nconvenience \nand the need \nto protect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\n11 years who— \n\n(a) are \nimmunocompromi\nsed and have \nalready received \nan additional dose \nof a COVID-19 \nvaccine, or \n\n(b) have already \nreceived a \nprimary vaccine \ncourse against \nCOVID-19 and \nhave become \nimmunocompromi\nsed since the \nadministration of \nthat primary \nvaccine course. \n\nThe booster doses \nshould be \nadministered in \nsuch volumes, at \nsuch intervals, in \nsuch manner and \nin such order of \nprioritisation \n(whether by \nreference to age, \nimmune status, \nliving \narrangements or \notherwise), as \nmay be specified \nin such \nrecommendations \nor guidelines. \n\nIn accordance \nwith relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth. \n\nNotwithstanding \nany directions to \nthe contrary in the \nsummary of \nproduct \ncharacteristics, the \nproduct shall only \nbe administered to \neligible \nindividuals who \nare 30 years of \nage or older and \n\nIntramuscular \n(IM) injection \n\nOne dose (0.5 \nmL) contains \n25 \nmicrograms of \nelasomeran \nand 25 \nmicrograms of \ndavesomeran, \na COVID-19 \nmRNA \nVaccine \n(embedded in \nlipid \nnanoparticles)\n. \n\nSpikevax \nbivalent \nOriginal/O\nmicron \nBA.4-5 (50 \nmicrograms\n/50 \nmicrograms\n)/mL \ndispersion \nfor \ninjection \nCOVID-19 \nmRNA \nVaccine \n(nucleoside \nmodified) \n\nActive \nimmunisatio\nn to prevent \nCOVID-19 \ncaused by \nSARS-CoV2 in \nindividuals \n30 years of \nage and \nolder who \nhave \npreviously \nreceived at \nleast \na primary \nvaccination \ncourse \nagainst \nCOVID-19. \n\n \n \n \n \n \n \n \n \n \n\f6 [11] \n\nhave previously \nreceived at least a \nprimary \nvaccination \ncourse against \nCOVID-19. \n\nThe product is to \nbe administered in \nsuch volumes, at \nsuch intervals, in \nsuch manner and \nin such order of \nprioritisation \n(whether by \nreference to age, \nemployment \nsector, pregnancy, \nliving \narrangements or \notherwise), as \nmay be specified \nin such \nrecommendations \nor guidelines with \nan interval of not \nless than 4 \nmonths, or 3 \nmonths in \nexceptional \ncircumstances, \nbetween \nadministration of \nthe product and \nthe last prior dose \nof a COVID-19 \nvaccine, or \nconfirmed SARSCOV-2 infection. \n\n”.", "text_norm": "3 eighth schedule (as amended regulation 3 regulation 2022) principal regulation amended inserting following additional entry 4 11 medicinal product form presentation product administered route administration column 3 intramuscular (im) injection intramuscular (im) injection column 1 comirnaty 3 microgram dose concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) paediatric pack comirnaty original micron ba.4-5 (5 5 microgram ) dose concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) column 2 concentrate dispersion injection (sterile concentrate) multidose vial must diluted use dilution one dose (0.2 ml) contains 3 microgram tozinameran covid-19 mrna vaccine (embedded lipid nanoparticles)  concentrate dispersion injection (sterile concentrate) multidose vial must diluted use dilution one dose (0.2 ml) contains 5 microgram tozinameran 5 microgram famtozinamer covid-19 mrna vaccine (embedded lipid nanoparticles) indication medicinal product may administere column 4 indicated active immunisatio n prevent covid-19 caused sars-cov2 virus individual aged 6 month 4 year time first dose active immunisatio n prevent covid-19 caused sars-cov2 child aged 5 11 year previously received least primary vaccination course covid-19 dosage condition administration place administration column 6 suitable appropriate place regard public convenience need protect health safety public safely administer product suitable appropriate place regard public convenience need protect health safety public safely administer product column 5 accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health subject informed consent obtained parent guardian administered course 3 dos (0.2ml) each accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health product administered eligible individual 5 -11 year age previously received least primary vaccination course covid-19 notwithstanding direction contrary summary product characteristic booster dose may administered child aged 5 11 5 suitable appropriate place regard public convenience need protect health safety public safely administer product 11 year who-- (a) immunocompromi sed already received additional dose covid-19 vaccine (b) already received primary vaccine course covid-19 become immunocompromi sed since administration primary vaccine course booster dos administered volume interval manner order prioritisation (whether reference age immune status living arrangement otherwise) may specified recommendation guideline accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health notwithstanding direction contrary summary product characteristic product shall administered eligible individual 30 year age older intramuscular (im) injection one dose (0.5 ml) contains 25 microgram elasomeran 25 microgram davesomeran covid-19 mrna vaccine (embedded lipid nanoparticles)  spikevax bivalent original micron ba.4-5 (50 microgram 50 microgram ) ml dispersion injection covid-19 mrna vaccine (nucleoside modified) active immunisatio n prevent covid-19 caused sars-cov2 individual 30 year age older previously received least primary vaccination course covid-19 6 11 previously received least primary vaccination course covid-19 product administered volume interval manner order prioritisation (whether reference age employment sector pregnancy living arrangement otherwise) may specified recommendation guideline interval le 4 month 3 month exceptional circumstance administration product last prior dose covid-19 vaccine confirmed sarscov-2 infection", "start_char": 5799, "end_char": 11127, "source_path": "downloads\\2023\\2023_0011.pdf", "extraction_method": "pdfminer", "checksum": "sha256:dd9cd72eedc5a9a04462a0c3d90a8a5c34d69e3b70edcdd8cd7ef3d1e55d9f74", "cross_refs": []}
{"doc_id": "si-2023-0011-reg-4", "parent_doc_id": "si-2023-0011", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 11 of 2023", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2023, "heading": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations", "text_raw": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations \nof 2022) to the Principal Regulations is amended by inserting the following \nadditional entries: \n\n“ \n\nMedicinal \nproduct \n\nForm and \npresentation of \nthe product \nadministered \n\nRoute of \nadministration \n\nColumn 3 \nIntramuscular \n(IM) Injection \n\nColumn 1 \nComirnaty 3 \nmicrograms/\ndose \nconcentrate \nfor \ndispersion \nfor \ninjection \nCOVID-19 \nmRNA \nVaccine \n(nucleoside \n\nColumn 2 \nConcentrate for \ndispersion for \ninjection (sterile \nconcentrate) in a \nmultidose vial \nthat must be \ndiluted before use. \n\nAfter dilution, one \ndose (0.2 mL) \ncontains 3 \nmicrograms of \n\nIndication for \nwhich the \nmedicinal \nproduct may \nbe \nadministered \nColumn 4 \nIndicated for \nactive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV-2 \nvirus, in \nindividuals \naged 6 months \nto 4 years at \nthe time of \n\nDosage and \nconditions of \nadministration \n\nColumn 5 \nIn accordance with \nrelevant \nrecommendations or \nguidelines issued by \nthe National \nImmunisation \nAdvisory Committee \nand accepted by the \nMinister for Health, \nsubject to informed \nconsent being \nobtained from a \n\n \n \n \n \n\fmodified) \nPaediatric \npack \n\nComirnaty \nOriginal/Omi\ncron BA.4-5 \n(5/5 \nmicrograms)/\ndose \nconcentrate \nfor \ndispersion \nfor injection \nCOVID-19 \nmRNA \nVaccine \n(nucleoside \nmodified) \n\ntozinameran, a \nCOVID-19 \nmRNA Vaccine \n(embedded in \nlipid \nnanoparticles). \n\nConcentrate for \ndispersion for \ninjection (sterile \nconcentrate) in a \nmultidose vial \nthat must be \ndiluted before use. \n\nAfter dilution one \ndose (0.2 mL) \ncontains 5 \nmicrograms of \ntozinameran and 5 \nmicrograms of \nfamtozinameran, \na \nCOVID-19 \nmRNA Vaccine \n(embedded in \nlipid \nnanoparticles) \n\n[11] 7 \n\ntheir first dose. \n\nparent or guardian. \n\nIntramuscular \n(IM) Injection \n\nActive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV-2, \nin children \naged 5 to 11 \nyears who \nhave \npreviously \nreceived at \nleast a primary \nvaccination \ncourse against \nCOVID-19 \n\nAdministered as a \ncourse of 3 doses (0.2 \nmL each). \n\nIn accordance with \nrelevant \nrecommendations or \nguidelines issued by \nthe National \nImmunisation \nAdvisory Committee \nand accepted by the \nMinister for Health. \n\nThe product is to be \nadministered to \neligible individuals \nwho are 5 -11 years \nof age and have \npreviously received at \nleast a primary \nvaccination course \nagainst COVID-19. \n\nNotwithstanding any \ndirections to the \ncontrary in the \nsummary of product \ncharacteristics, a \nbooster dose may be \nadministered to \nchildren aged 5 to 11 \nyears who— \n\n(a) are \nimmunocompromised \nand have already \nreceived an additional \ndose of a COVID-19 \nvaccine, or \n\n(b) have already \nreceived a primary \nvaccine course \nagainst COVID-19 \nand have become \nimmunocompromised \nsince the \nadministration of that \nprimary vaccine \ncourse. \n\nThe booster doses \nshould be \nadministered in such \nvolumes, at such \nintervals, in such \nmanner and in such \norder of prioritisation \n(whether by reference \nto age, immune \nstatus, living \narrangements or \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f8 [11] \n\nOne dose (0.5 \nmL) contains \n25 micrograms of \nelasomeran \nand 25 \nmicrograms of \ndavesomeran, a \nCOVID-19 \nmRNA Vaccine \n(embedded in \nlipid \nnanoparticles). \n\nSpikevax \nbivalent \nOriginal/Omi\ncron BA.4-5 \n(50 \nmicrograms/\n50 \nmicrograms)/\nmL \ndispersion \nfor \ninjection \nCOVID-19 \nmRNA \nVaccine \n(nucleoside \nmodified) \n\nIntramuscular \ninjection \n\nActive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV-2 \nin individuals \n30 years of \nage and older \nwho have \npreviously \nreceived at \nleast \na primary \nvaccination \ncourse against \nCOVID-19. \n\n”. \n\notherwise), as may be \nspecified in such \nrecommendations or \nguidelines. \nIn accordance with \nrelevant \nrecommendations or \nguidelines issued by \nthe National \nImmunisation \nAdvisory Committee \nand accepted by the \nMinister for Health. \n\nNotwithstanding any \ndirections to the \ncontrary in the \nsummary of product \ncharacteristics, the \nproduct shall only be \nadministered to \neligible individuals \nwho are 30 years of \nage or older and have \npreviously received at \nleast a primary \nvaccination course \nagainst COVID-19. \n\nThe product is to be \nadministered in such \nvolumes, at such \nintervals, in such \nmanner and in such \norder of prioritisation \n(whether by reference \nto age, employment \nsector, pregnancy, \nliving arrangements \nor otherwise), as may \nbe specified in such \nrecommendations or \nguidelines with an \ninterval of not less \nthan 4 months , or 3 \nmonths in exceptional \ncircumstances, \nbetween \nadministration of the \nproduct and the last \nprior dose of a \nCOVID-19 vaccine, \nor confirmed SARSCOV-2 infection. \n\n \n \n \n \n \n \n \n \n\f[11] 9 \n\nGIVEN under my Official Seal, \n\n23 January, 2023. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f10 [11]", "text_norm": "4 twelfth schedule (as amended regulation 4 regulation 2022) principal regulation amended inserting following additional entry medicinal product form presentation product administered route administration column 3 intramuscular (im) injection column 1 comirnaty 3 microgram dose concentrate dispersion injection covid-19 mrna vaccine (nucleoside column 2 concentrate dispersion injection (sterile concentrate) multidose vial must diluted use dilution one dose (0.2 ml) contains 3 microgram indication medicinal product may administered column 4 indicated active immunisation prevent covid-19 caused sars-cov-2 virus individual aged 6 month 4 year time dosage condition administration column 5 accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health subject informed consent obtained modified) paediatric pack comirnaty original omi cron ba.4-5 (5 5 micrograms) dose concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) tozinameran covid-19 mrna vaccine (embedded lipid nanoparticles) concentrate dispersion injection (sterile concentrate) multidose vial must diluted use dilution one dose (0.2 ml) contains 5 microgram tozinameran 5 microgram famtozinameran covid-19 mrna vaccine (embedded lipid nanoparticles) 11 7 first dose parent guardian intramuscular (im) injection active immunisation prevent covid-19 caused sars-cov-2 child aged 5 11 year previously received least primary vaccination course covid-19 administered course 3 dos (0.2 ml each) accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health product administered eligible individual 5 -11 year age previously received least primary vaccination course covid-19 notwithstanding direction contrary summary product characteristic booster dose may administered child aged 5 11 year who-- (a) immunocompromised already received additional dose covid-19 vaccine (b) already received primary vaccine course covid-19 become immunocompromised since administration primary vaccine course booster dos administered volume interval manner order prioritisation (whether reference age immune status living arrangement 8 11 one dose (0.5 ml) contains 25 microgram elasomeran 25 microgram davesomeran covid-19 mrna vaccine (embedded lipid nanoparticles) spikevax bivalent original omi cron ba.4-5 (50 microgram 50 micrograms) ml dispersion injection covid-19 mrna vaccine (nucleoside modified) intramuscular injection active immunisation prevent covid-19 caused sars-cov-2 individual 30 year age older previously received least primary vaccination course covid-19  otherwise) may specified recommendation guideline accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health notwithstanding direction contrary summary product characteristic product shall administered eligible individual 30 year age older previously received least primary vaccination course covid-19 product administered volume interval manner order prioritisation (whether reference age employment sector pregnancy living arrangement otherwise) may specified recommendation guideline interval le 4 month 3 month exceptional circumstance administration product last prior dose covid-19 vaccine confirmed sarscov-2 infection 11 9 given official seal 23 january 2023 stephen donnelly minister health 10 11", "start_char": 11127, "end_char": 15974, "source_path": "downloads\\2023\\2023_0011.pdf", "extraction_method": "pdfminer", "checksum": "sha256:dd9cd72eedc5a9a04462a0c3d90a8a5c34d69e3b70edcdd8cd7ef3d1e55d9f74", "cross_refs": []}
{"doc_id": "si-2023-0011-explanatory-note", "parent_doc_id": "si-2023-0011", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 11 of 2023", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2023, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to amend the relevant schedules in relation \nto the COVID-19 vaccines to provide for the administration of a bivalent \nadapted Covid vaccine, to add an additional paediatric product formulation of \nComirnaty product to facilitate vaccination of children from 6 months to 4 \nyears, and to provide for a further bivalent adapted Covid vaccine as a booster \ndose for persons aged 5 to 11. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) Regulations 2023. \n\n \n \n \n \n \n \n \n \n\f[11] 11 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.50 \n\n(DH-468) 75. 1/23. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation amend relevant schedule relation covid-19 vaccine provide administration bivalent adapted covid vaccine add additional paediatric product formulation comirnaty product facilitate vaccination child 6 month 4 year provide bivalent adapted covid vaccine booster dose person aged 5 11 regulation may cited medicinal product (prescription control supply) (amendment) regulation 2023 11 11 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.50 (dh-468) 75 1 23 propylon", "start_char": 15974, "end_char": 17255, "source_path": "downloads\\2023\\2023_0011.pdf", "extraction_method": "pdfminer", "checksum": "sha256:dd9cd72eedc5a9a04462a0c3d90a8a5c34d69e3b70edcdd8cd7ef3d1e55d9f74", "cross_refs": []}
